Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease

Takuya Oda, Hazumu Nagata, Yasutaka Nakashima, Etsuro Nanishi, Yui Takada, Manao Nishimura, Eiji Kubo, Ken Hatae, Shouichi Ohga

Research output: Contribution to journalArticle

Abstract

Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.

Original languageEnglish
Pages (from-to)227-230
Number of pages4
JournalJournal of Pediatrics
Volume214
DOIs
Publication statusPublished - Nov 2019

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease'. Together they form a unique fingerprint.

  • Cite this